Invention Grant
- Patent Title: Mitochondrial inhibitors for use in culturing pluripotent stem cells
-
Application No.: US15319319Application Date: 2015-06-19
-
Publication No.: US10196604B2Publication Date: 2019-02-05
- Inventor: David Alvin Tyvoll , Christopher S. Navara , James P. Collman , Christopher Jeffrey Barile
- Applicant: The Board of Trustees of the Leland Stanford Junior University , BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
- Applicant Address: US CA Stanford US TX Austin
- Assignee: The Board of Trustees of the Leland Stanford Junior University,Board of Regents of the University of Texas System
- Current Assignee: The Board of Trustees of the Leland Stanford Junior University,Board of Regents of the University of Texas System
- Current Assignee Address: US CA Stanford US TX Austin
- Agency: Bozicevic, Field & Francis LLP
- Agent Brian E. Davy
- International Application: PCT/US2015/036787 WO 20150619
- International Announcement: WO2015/196139 WO 20151223
- Main IPC: C12N5/00
- IPC: C12N5/00 ; C12N5/0735 ; C07D257/06 ; C07D257/04
Abstract:
Disclosed are certain heterocyclic organic compounds that inhibit mitochondrial respiration and also lead to the maintenance of pluripotency of human embryonic stem cells in culture, even in the presence of oxygen. Exemplified are compounds, such as substituted 5-aminotetrazoles, which are reversible mitochondrial inhibitors. The pluripotency of the stem cells after culture is verified by the overexpression of pluripotent stem cell markers, exemplified by at least one of the genes NANOG, OCT4, and SURVIVIN after periods of culture in ambient oxygen.
Public/Granted literature
- US20170130198A1 MITOCHONDRIAL INHIBITORS FOR USE IN CULTURING PLURIPOTENT STEM CELLS Public/Granted day:2017-05-11
Information query
